DOCSLIB.ORG

Engineered Proteins As Tools to Understand Ubiquitin Signaling

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Engineered Proteins As Tools to Understand Ubiquitin Signaling University of Massachusetts Amherst ScholarWorks@UMass Amherst Doctoral Dissertations Dissertations and Theses December 2020 Engineered proteins as tools to understand ubiquitin signaling Lin Hui Chang University of Massachusetts Amherst Follow this and additional works at: https://scholarworks.umass.edu/dissertations_2 Part of the Chemistry Commons, and the Life Sciences Commons Recommended Citation Chang, Lin Hui, "Engineered proteins as tools to understand ubiquitin signaling" (2020). Doctoral Dissertations. 2001. https://doi.org/10.7275/18414115 https://scholarworks.umass.edu/dissertations_2/2001 This Open Access Dissertation is brought to you for free and open access by the Dissertations and Theses at ScholarWorks@UMass Amherst. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of ScholarWorks@UMass Amherst. For more information, please contact [email protected]. Engineered Proteins As Tools To Understand Ubiquitin Signaling A Dissertation Presented by LIN HUI CHANG Submitted to the Graduate School of the University of Massachusetts Amherst in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY September 2020 Chemistry © Copyright by Lin Hui Chang 2020 All Rights Reserved Engineered Proteins As Tools To Understand Ubiquitin Signaling A Dissertation Presented by LIN HUI CHANG Approved as to style and content by: ______________________________ Eric R. Strieter, Chair ______________________________ Lynmarie K. Thompson, Member ______________________________ Min Chen, Member ______________________________ Scott C. Garman, Outside Member ______________________________ Ricardo B. Metz, Department Head Chemistry Department ACKNOWLEDGEMENT I would like to thank my advisor, Eric Strieter, for his guidance and encouragement. I still remember vividly that after my transfer to University of Massachusetts-Amherst, that was a time when I was struggling with my research; he has asked me to focus on yeast display and has accompanied me to seek advice from other faculty member in the field. Eric is very passion in science and will always come into the lab with different ideas, sometimes they could be weird, but most of the times, his ideas are thought-provoking. His attitude in science will continue motivate me to strive harder in my future career. I would also like to thank my committee members, Prof. Lynmarie Thompson, Prof. Min Chen and Prof. Scott Garman for their advices in my research. I really appreciate working with the core facilities manager, especially for Dr. Amy Burnside, Dr. Lizz Bartlett, Dr. Ravi Ranjan, Dr. James Chambers, and Dr. Steve Eyles for being always available every time I have questions with the instruments or experiments. I would like to especially thank Prof. Sarah Moore from Smith College and her student, Allison Sirois for helping me with yeast display. I am fortunate to work with my group members. They have taught me how to perform experiments and helped me with my writing and presentation for my exam. Robert, Ambar, Sean, Kirandeep and Jiale, whom I know from Madison. Because of them, I have the courage to move to Amherst to challenge the new environment. I would like to thank the group members in Amherst, Sandor, iv Yanfeng, Heather, Fangying, Rehab and Rakesh. Thank you all for the numerous supports, and sharing the ideas and materials with me. Also, I would like to thank the Chemistry Department. DV, jms, and Chandra who help me with the administrative documents. Vicki and Kris for the helps with the issues regarding purchasing. Marv, Bob, and Ryan, for fixing our instruments and help us every time something wrong in the lab. John, Gary, and Nikki who come into rescue when my computer decided to “have an attitude”. Dennis who is so friendly, and a trip to the stockroom is always a good short break from the experiments. Last but not least, I am very grateful for families and friends. Dad and mum, who always encourage me every time I am doubtful of myself and my sisters, Lin Zhi, Lin June and Lin-li who support me to pursuit my graduate study. My relatives in New York, who is like a second family to me and make sure I adapt to the life in USA. Also, I would like to thank to my friends, especially Ying Ji, Kong, and 7th floor members for all the morale support throughout my graduate career. v ABSTRACT ENGINEERED PROTEINS AS TOOLS TO UNDERSTAND UBIQUITIN SIGNALING SEPTEMBER 2020 LIN HUI CHANG, B. S., UNIVERSITY OF TOKYO M.S., UNIVERSITY OF WISCONSIN-MADISON PH. D., UNIVERSITY OF MASSACHUSETTS AMHERST Directed by Professor Eric R. Strieter Ubiquitin is a 76 amino acids protein that is evolutionary conserved in eukaryotes. It is an important signaling molecule in a plethora biological events, such as protein degradation, DNA damage response, and transcription. This thesis aims to develop engineered protein as a tool to study ubiquitin signaling. Through targeted mutagenesis and directed evolution, a deubiquitinase is reprogrammed into a transamidase, which lead to the generation of ubiquitin- protein conjugates with discrete ubiquitin linkages through auto-ubiquitination. These ubiquitin-protein conjugates could be used as a model substrate to profile their interaction of different ubiquitin interacting proteins. In addition, using directed evolution and deep sequencing, a nanobody-based binder targeting a deubiquitinase is engineered. This nanobody could be utilized as an intracellular probe to study the regulation of the deubiquitinase with great spatial and temporal control. vi TABLE OF CONTENTS Page ACKNOWLEDGEMENT .......................................................................................iv ABSTRACT ..........................................................................................................vi LIST OF TABLES ................................................................................................. x LIST OF FIGURES ...............................................................................................xi CHAPTER 1: INTRODUCTION .............................................................................................. 1 Ubiquitination machinery ................................................................................... 1 How are different ubiquitin conjugates recognized by their interacting proteins? ........................................................................................................... 3 How the specificities of ubiquitin interacting protein are regulated? .................. 5 Regulation of the proteasome associated ubiquitin receptors and deubiquitinases .............................................................................................. 5 Protein engineering in ubiquitin system ........................................................... 12 Rational design and directed evolution ........................................................ 12 Engineered protein as tools to study ubiquitin system ................................. 16 Forward to thesis ............................................................................................. 18 References ...................................................................................................... 20 2: REPROGRAMMING A DEUBIQUITINASE INTO A TRANSAMIDASE .......... 26 Abstract ........................................................................................................... 26 vii Page Introduction ..................................................................................................... 27 Result .............................................................................................................. 32 Targeted mutagenesis ................................................................................. 32 Autoubiquitination of Yuh1m ........................................................................ 38 Directed evolution of Yuh1qm ...................................................................... 43 Profiling DUBs activities using Ubiquitin-Yuh1 conjugates ........................... 49 Discussion and Future Directions.................................................................... 55 Materials and Methods .................................................................................... 58 References ...................................................................................................... 68 3: ENGINEER A NANOBODY SPECIFIC TOWARDS PROTEASOME- ASSOCIATED UCH37 ........................................................................................ 72 Abstract ........................................................................................................... 72 Introduction ..................................................................................................... 73 Result .............................................................................................................. 77 Generation of the UCH37 nanobodies ......................................................... 77 Affinity maturation of the proteasome-associated UCH37 specific Nbs ....... 81 Characterization of Nanobodies ................................................................... 87 Nanobodies as intrabodies for proteasome-associated UCH37 .................. 94 Discussion and Future directions .................................................................... 97 Materials and Methods .................................................................................. 100 viii Page References ...................................................................................................
Load more

Recommended publications
  • Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases
    Antibodies 2015, 4, 170-196; doi:10.3390/antib4030170 OPEN ACCESS antibodies ISSN 2073-4468 www.mdpi.com/journal/antibodies Review Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases Marta Westwood * and Alastair D. G. Lawson Structural Biology, UCB, 216 Bath Road, Slough, SL1 3WE UK; E-Mail: [email protected]. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +44-1-753-534-655 (ext.7749); Fax: +44-1-753-536-632. Academic Editor: Dimiter S. Dimitrov Received: 13 May 2015 / Accepted: 9 July 2015 / Published: 15 July 2015 Abstract: Assembly of misfolded proteins into fibrillar deposits is a common feature of many neurodegenerative diseases. Developing effective therapies to these complex, and not yet fully understood diseases is currently one of the greatest medical challenges facing society. Slow and initially asymptomatic onset of neurodegenerative disorders requires profound understanding of the processes occurring at early stages of the disease including identification and structural characterisation of initial toxic species underlying neurodegeneration. In this review, we chart the latest progress made towards understanding the multifactorial process leading to amyloid formation and highlight efforts made in the development of therapeutic antibodies for the treatment of amyloid-based disorders. The specificity and selectivity of conformational antibodies make them attractive research probes to differentiate between transient states preceding formation of mature fibrils and enable strategies for potential therapeutic intervention to be considered. Keywords: antibody; amyloids; conformation; prion; Alzheimer’s; Parkinson’s; fibrils, tau; Huntingtin; protein misfolding 1. Introduction Correct protein folding is crucial for maintaining healthy biological functions.
    [Show full text]
  • Rapid Selection of Specific MAP Kinase-Binders from Designed Ankyrin Repeat Protein Libraries
    Protein Engineering, Design & Selection vol. 19 no. 5 pp. 219–229, 2006 Published online March 21, 2006 doi:10.1093/protein/gzl004 Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries Patrick Amstutz1,4,5, Holger Koch1,4, H. Kaspar Binz1, form in this milieu. For this reason, antibodies were Stefan A. Deuber2 and Andreas Plu¨ckthun1,3 engineered for higher intracellular stability with some success 1 et al ¨ ¨ Biochemisches Institut der Universita¨tZu¨rich, Winterthurerstrasse 190, (Proba ., 1998; Worn and Pluckthun, 1998; Desiderio CH-8057 Zu¨rich, Switzerland and 2Institut fu¨r Medizinische Virologie der et al., 2001; Visintin et al., 2002), but the number of selected Universita¨tZu¨rich, Gloriastrasse 30, Zu¨rich, Switzerland and active binders is usually limited (Tanaka and Rabbitts, 3To whom correspondence should be addressed. 2003; Koch et al., 2006). These results can be explained by E-mail: [email protected] the selection pressure, which not only places demands on 4These authors contributed equally to this work. 5 specific binding but also requires stability under reducing Present address: Molecular Partners AG, c/o Universita¨tZu¨rich, conditions. Winterthurerstrasse 190, CH-8057 Zu¨rich, Switzerland To overcome these limitations of immunoglobulin We describe here the rapid selection of specific MAP-kinase domains, a variety of novel scaffolds for the generation of binders from a combinatorial library of designed ankyrin antibody-like binding molecules, some of them possessing repeat proteins (DARPins). A combined in vitro/in vivo selec- very favorable biophysical properties, has been developed tion approach, based on ribosome display and the protein (Nygren and Skerra, 2004; Binz et al., 2005).
    [Show full text]
  • Peptide Tag Systems That Spontaneously Form An
    (19) TZZ ¥_T (11) EP 2 534 484 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G01N 33/531 (2006.01) C07K 14/315 (2006.01) 19.11.2014 Bulletin 2014/47 C12N 15/00 (2006.01) (21) Application number: 11706621.7 (86) International application number: PCT/GB2011/000188 (22) Date of filing: 11.02.2011 (87) International publication number: WO 2011/098772 (18.08.2011 Gazette 2011/33) (54) PEPTIDE TAG SYSTEMS THAT SPONTANEOUSLY FORM AN IRREVERSIBLE LINK TO PROTEIN PARTNERS VIA ISOPEPTIDE BONDS PEPTIDMARKIERUNGSSYSTEME MIT SPONTANER BILDUNG EINER IRREVERSIBLEN VERBINDUNG ZU PROTEINPARTNERN ÜBER ISOPEPTIDBINDUNGEN SYSTÈMES DE MARQUAGE PEPTIDIQUE QUI FORMENT SPONTANÉMENT UNE LIAISON IRRÉVERSIBLE AVEC DES PARTENAIRES PROTÉIQUES PAR L’INTERMÉDIAIRE DE LIAISONS ISOPEPTIDIQUES (84) Designated Contracting States: • TOMINAGA J ET AL: "Design of a specific peptide AL AT BE BG CH CY CZ DE DK EE ES FI FR GB tagthat affords covalent and site- specificenzyme GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO immobilization catalyzed by microbial PL PT RO RS SE SI SK SM TR transglutaminase", BIOMACROMOLECULES JULY/AUGUST 2005 AMERICAN CHEMICAL (30) Priority: 11.02.2010 GB 201002362 SOCIETY US, vol. 6, no. 4, July 2005 (2005-07), pages 2299-2304, XP002631438, DOI: DOI: (43) Date of publication of application: 10.1021/BM050193O 19.12.2012 Bulletin 2012/51 • DONG RUI-PING ET AL: "Characterization of T cell epitopes restricted by HLA-DP9 in (73) Proprietor: Isis Innovation Limited streptococcal M12 protein", JOURNAL OF Summertown, Oxford OX2 7SQ (GB) IMMUNOLOGY, vol.
    [Show full text]
  • Assessment Genetics Mutations in Genes AMELX, ENAM, MMP20 and FAM83H in Inducate Amelogenesis Imperfecta Syndrome Shahin Asadi*
    Haematology Open Access Open Journal Review Assessment Genetics Mutations in Genes AMELX, ENAM, MMP20 and FAM83H in Inducate Amelogenesis Imperfecta Syndrome Shahin Asadi* Director of the Division of Medical Genetics and Molecular Research, Molecular Medicine, Genetics Harvard University, USA *Correspondence to: Shahin Asadi; Director of the Division of Medical Genetics and Molecular Research, Molecular Medicine, Genetics Harvard University, USA; E-mail: [email protected] Received: March 28th, 2019; Revised: March 29th, 2019; Accepted: March 29th, 2019; Published: March 30th, 2019 Citation: Carlos TJ, Ignacio HD, Xavier SI, Ariel LE. Assessment genetics mutations in genes AMELX,ENAM, MMP20 and FAM83H in inducate amelogenesis imperfecta syndrome. Haemat Open A Open J. 2019; I(1): 5-8. ABSTRACT Defective amelogenesis syndrome is a genetic disorder in the development of teeth. The researchers described at least 14 types of incomplete amelogenesis disorders. Mutations in the AMELX, ENAM, MMP20, and FAM83H genes can cause malformation of the amelogenesis syndrome. Keywords: Amelogenesis syndrome, AMELX, ENAM, MMP20, FAM83H genes, Teeth disorders.. GENERALIZATIONS OF INCOMPLETE AMELOGENESIS cific dental disorders and hereditary patterns. Additionally, incomplete SYNDROME amelogenesis syndrome can occur alone without any other symptoms or symptoms, or it can occur as part of a syndrome that affects different Defective amelogenesis syndrome is a genetic disorder in the develop- parts of the body.2 ment of teeth. This condition causes the teeth to be abnormally small, colored, pitted or perforated, and are prone to wear and breakage. Other Figure 2. Another view of dental disorders in amelogenesis syndrome dental disorders may also occur in incomplete amelogenesis syndrome. These defects, which vary among people affected, can affect the teeth (the child) and permanent teeth (adults).1 Figure 1.
    [Show full text]
  • Discovery of Genes by Phylocsf Supplemental
    Supplemental Materials for Discovery of high-confidence human protein-coding genes and exons by whole-genome PhyloCSF helps elucidate 118 GWAS loci Supplemental Methods ....................................................................................................................... 2 Supplemental annotation methods ........................................................................................................... 2 Manual annotation overview ...................................................................................................................................... 2 Summary diagram for the workflow used in this study ................................................................................. 3 Transcriptomics analysis ............................................................................................................................................. 3 Comparative annotation ............................................................................................................................................... 4 Overlap of novel annotations with transposon sequences ........................................................................... 6 Assessing the novelty of annotations ...................................................................................................................... 7 Additional considerations for the annotation of PCCRs in other species ............................................... 7 PhyloCSF and browser tracks ....................................................................................................................
    [Show full text]
  • Affimer Proteins Inhibit Immune Complex Binding to Fcγriiia with High Specificity Through Competitive and Allosteric Modes of Action
    Affimer proteins inhibit immune complex binding to FcγRIIIa with high specificity through competitive and allosteric modes of action James I. Robinsona,b, Euan W. Baxtera,b,1, Robin L. Owenc,1, Maren Thomsend,1, Darren C. Tomlinsond,e,1, Mark P. Waterhousea,b,1, Stephanie J. Wina,b, Joanne E. Nettleshipf,g, Christian Tiedee, Richard J. Fosterd,h, Raymond J. Owensf,g, Colin W. G. Fishwickd,h, Sarah A. Harrisd,i, Adrian Goldmane,j, Michael J. McPhersond,e,2, and Ann W. Morgana,b,2 aLeeds Institute of Rheumatic and Musculoskeletal Medicine, School of Medicine, University of Leeds, Leeds LS9 7TF, United Kingdom; bNational Institute of Health Research-Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds LS7 4SA, United Kingdom; cDiamond Light Source, Didcot OX11 0DE, United Kingdom; dAstbury Centre for Structural and Molecular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom; eBioScreening Technology Group, School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom; fOxford Protein Production Facility-United Kingdom Research Complex at Harwell, Rutherford Appleton Laboratory, Oxford OX11 0FA, United Kingdom; gDivision of Structural Biology, Wellcome Trust Centre for Genomic Medicine, Nuffield Department of Medicine, Oxford University, Oxford OX3 7BN, United Kingdom; hSchool of Chemistry, University of Leeds, Leeds LS2 9JT, United Kingdom; iSchool of Physics and Astronomy, University of Leeds, Leeds LS2 9JT, United Kingdom; and jFaculty of Biological and Environmental Sciences, University of Helsinki, FIN-0014 Helsinki, Finland Edited by Lawrence Steinman, Stanford University School of Medicine, Stanford, CA, and approved November 17, 2017 (received for review May 15, 2017) Protein–protein interactions are essential for the control of cellular domains and chains, poor stability, high production costs, and functions and are critical for regulation of the immune system.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Affimer Technology Nov 2017
    Non-confidential Technical Introduction to the Affimer® Technology for Therapeutics and Reagents Dr. Alastair Smith Chief Executive, Avacta Group plc Introduction Avacta Group plc AIM: AVCT • 80 staff over two sites: • 1300 m2 of bespoke laboratory, production and logistics space in Wetherby. • 790 m2 of bespoke laboratory space in Cambridge. • Balance sheet to support existing plans. Wetherby • Experienced management team with interests aligned to shareholders. • Strongly supportive shareholder base. Cambridge London Shareholders >5% . IP Group plc 24.8% Lombard Odier 11.4% Aviva 9.6% Baillie Gifford 7.2% Ruffer LLP 7.1% Fidelity 5.9% J O Hambro 5.7% © Avacta Group plc 2 Leadership Team Dr Alastair Smith, CEO Dr Matt Johnson, CTO Mr Tony Gardiner, CFO • Over 10 years experience as a public • Genetics & Microbiology Molecular • Joined Avacta from AHR, an company CEO Biology international architecture practice • Was a leading UK biophysicist - founded • 8 years at Abcam becoming global • Chief Financial Officer of AIM listed Avacta in 2006 Head of R&D Fusion IP plc 2007 – 2011 which was acquired by IP Group plc in 2014 • World class scientific and technical • Joined Avacta in 2014 knowledge with a highly commercial • Joined Avacta in 2016 mindset Dr Philippe Cotrel, CCO Dr Amrik Basran, CSO • Over 20 years’ commercial experience in senior • Over 10 years’ experience of both the biotech and positions in Amersham Pharmacia Biotech, Oxford pharma industries Glycosciences, Affymetrix and Abcam • Director of Protein Biosciences at Domantis, Head of • Commercial Director of Abcam since 2008 – grew Topical Delivery (Biopharm) at GSK revenue from £36.7m to £144m over a 7-year period • Joined Avacta in 2013 • Joined Avacta in 2016 © Avacta Group plc 3 Affimer Technology Affimer®: A proprietary protein scaffold with key technical benefits What is an Affimer? Binding Surface • Based on a naturally occurring proteins (cystatins) and engineered to stably display two loops which create a binding surface.
    [Show full text]
  • Nanobodies Right in the Middle: Intrabodies As Toolbox to Visualize and Modulate Antigens in the Living Cell
    biomolecules Review Nanobodies Right in the Middle: Intrabodies as Toolbox to Visualize and Modulate Antigens in the Living Cell Teresa R. Wagner 1,2 and Ulrich Rothbauer 1,2,* 1 Pharmaceutical Biotechnology, Eberhard Karls University Tuebingen, 72076 Tuebingen, Germany; [email protected] 2 Natural and Medical Sciences Institute, University of Tuebingen, 72770 Reutlingen, Germany * Correspondence: [email protected]; Tel.: +49-7121-5153-0415; Fax: +49-7121-5153-0816 Received: 30 November 2020; Accepted: 18 December 2020; Published: 21 December 2020 Abstract: In biomedical research, there is an ongoing demand for new technologies to elucidate disease mechanisms and develop novel therapeutics. This requires comprehensive understanding of cellular processes and their pathophysiology based on reliable information on abundance, localization, post-translational modifications and dynamic interactions of cellular components. Traceable intracellular binding molecules provide new opportunities for real-time cellular diagnostics. Most prominently, intrabodies derived from antibody fragments of heavy-chain only antibodies of camelids (nanobodies) have emerged as highly versatile and attractive probes to study and manipulate antigens within the context of living cells. In this review, we provide an overview on the selection, delivery and usage of intrabodies to visualize and monitor cellular antigens in living cells and organisms. Additionally, we summarize recent advances in the development of intrabodies as cellular biosensors and their application to manipulate disease-related cellular processes. Finally, we highlight switchable intrabodies, which open entirely new possibilities for real-time cell-based diagnostics including live-cell imaging, target validation and generation of precisely controllable binding reagents for future therapeutic applications. Keywords: nanobody; intrabody; phage display; live-cell imaging; biosensors; target validation 1.
    [Show full text]
  • Designer Oncolytic Adenovirus: Coming of Age
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 21 May 2018 doi:10.20944/preprints201805.0273.v1 Designer Oncolytic Adenovirus: Coming of Age Alexander T. Baker1, Carmen Aguirre-Hernandez2, Gunnel Hallden2, Alan L. Parker1* 1 Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, CF14 4XN, United Kingdom 2 Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, EC1M 6BQ, United Kingdom *Corresponding author Dr. Alan L. Parker Division of Cancer and Genetics Henry Wellcome Building Cardiff University School of Medicine Heath Park Cardiff CF14 4XN Email: [email protected] Keywords: adenovirus; oncolytic; targeting; virotherapy; cancer; αvβ6 integrin; immunotherapy; tropism 1 © 2018 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 21 May 2018 doi:10.20944/preprints201805.0273.v1 Contents 1. Introduction: ................................................................................................................................... 4 2. Replication-selective adenoviruses ..................................................................................................... 6 2.1 Combination of oncolytic adenoviruses with chemotherapy ..................................................... 11 3. Oncolytic immunotherapy ................................................................................................................ 12 4. Tropism modification strategies ......................................................................................................
    [Show full text]
  • Improving Protein Therapeutics Through Quantitative Molecular Engineering Approaches and a Cell-Based Oral Delivery Platform
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2013 Improving Protein Therapeutics Through Quantitative Molecular Engineering Approaches and A Cell-Based Oral Delivery Platform Ting Wun Ng University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Biomedical Commons Recommended Citation Ng, Ting Wun, "Improving Protein Therapeutics Through Quantitative Molecular Engineering Approaches and A Cell-Based Oral Delivery Platform" (2013). Publicly Accessible Penn Dissertations. 784. https://repository.upenn.edu/edissertations/784 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/784 For more information, please contact [email protected]. Improving Protein Therapeutics Through Quantitative Molecular Engineering Approaches and A Cell-Based Oral Delivery Platform Abstract Proteins, with their ability to perform a variety of highly specific biological functions, have emerged as an important class of therapeutics. However, to fully harness their therapeutic potential, proteins often need to be optimized by molecular engineering; therapeutic efficacy can be improved by modulating protein properties such as binding affinity/specificity, half-life, bioavailability, and immunogenicity. In this work, we first present an introductory example in which a mechanistic mathematical model was used to improve target selection for directed evolution of an aglycosylated Fc domain of an antibody to enhance
    [Show full text]
  • EURL ECVAM Recommendation on Non-Animal-Derived Antibodies
    EURL ECVAM Recommendation on Non-Animal-Derived Antibodies EUR 30185 EN Joint Research Centre This publication is a Science for Policy report by the Joint Research Centre (JRC), the European Commission’s science and knowledge service. It aims to provide evidence-based scientific support to the European policymaking process. The scientific output expressed does not imply a policy position of the European Commission. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this publication. For information on the methodology and quality underlying the data used in this publication for which the source is neither Eurostat nor other Commission services, users should contact the referenced source. EURL ECVAM Recommendations The aim of a EURL ECVAM Recommendation is to provide the views of the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) on the scientific validity of alternative test methods, to advise on possible applications and implications, and to suggest follow-up activities to promote alternative methods and address knowledge gaps. During the development of its Recommendation, EURL ECVAM typically mandates the EURL ECVAM Scientific Advisory Committee (ESAC) to carry out an independent scientific peer review which is communicated as an ESAC Opinion and Working Group report. In addition, EURL ECVAM consults with other Commission services, EURL ECVAM’s advisory body for Preliminary Assessment of Regulatory Relevance (PARERE), the EURL ECVAM Stakeholder Forum (ESTAF) and with partner organisations of the International Collaboration on Alternative Test Methods (ICATM). Contact information European Commission, Joint Research Centre (JRC), Chemical Safety and Alternative Methods Unit (F3) Address: via E.
    [Show full text]